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	Gene targeting in mouse embryonal stem cells allows the disruption of any cloned gene in a predetermined fashion (1,2). Essentially two types of vectors can be used to create gene disruptions by homologous recombination (3). Sequence replacement vectors (type) are designed so that a dominant selectable marker is flanked by target-DNA homology and disrupts coding sequence. In this way the non-homologous sequences at the cut ends of the vector are removed. This is the basis of the positive-negative selection (PNS) enrichment strategy (4) which has become the most widely used  targeting strategy. The alternative vector type is sequence insertion (O type). These vectors contain an uninterrupted stretch of target-homology with exonic sequence being contiguous with plasmid DNA. Insertional vectors are linearised within the region of homology and recombine at this double stranded break and insert the whole construct into the endogenous locus. Two groups have reported comparisons between the targeting efficiencies of sequence replacement and sequence insertion vectors to the murine Hypoxanthine phosphoribosyl transferase (Hprt) gene. Hasty et al. (5) report a nine-fold improved frequency of targeting with an insertional versus a replacement vector using non-isogenic DNA. Deng and Capecchi (6) however, did not find any difference between vector types using isogenic DNA and they postulate that the results of Hasty et al. (5) were distorted by an unfavourable distribution of heterology between the targeting vector and the target locus. Only some of the parameters controlling gene targeting frequency have been defined.  An increased length of homology enhances the targeting frequency to the Hprt gene (3,6,7). In addition, the use of isogenic DNA increases the frequency significantly at least for some genes (6,8).  Additional factors that may influence targeting frequency include the intrinsic recombinational status of a region of DNA and that of the recipient cells (9). The majority of the reported data on targeting frequencies has been generated by vectors directed to the Hprt gene as both positive and negative selection is possible. Here we describe the effect of the variation of vector design on targeting frequency directed to the Cftr gene, a non-selectable locus. We have previously reported targeting the murine cystic fibrosis transmembrane conductance regulator (Cftr) gene in the E14 embryonal stem cell line using an insertional vector containing 3.5 kb of isogenic DNA (10). The frequency of  homologous recombination was 1 in 46 (2.2%). This frequency is significantly higher than those reported by two other groups using isogenic DNA sequence replacement constructs (11,12). All three groups were targeting the same region (at and around exon 10 of the Cftr gene), although the replacement targeting constructs contained longer stretches of genomic DNA. Despite this, Koller et al. using 7.8 kb of homology (11) quote 1/2500 (0.04%) and Ratcliffe et al. (12) report 1/1470 using 5.5 kb of homology (0.07%) as their respective targeting frequencies. Thus, we observed a ~50-fold higher targeting frequency using an insertional vector. Here we describe a further improvement in gene targeting frequency, achieved first by a modest increase in the absolute length of the target-DNA homology and second by altering the distribution of homology flanking the site of linearisation, to give a targeting frequency of ~10%.
	Experiments were performed to examine factors influencing the efficiency of gene targeting at the Cftr locus. The insertion vector pIV3.5H (Fig. 1A) is that used previously to target the murine Cftr gene in embryonal stem cells (10) and used to create a viable mouse model for cystic fibrosis (13). This vector was modified to increase the target region of homology from 3.5 kb to 4.3 kb whilst introducing point mutations into exon 10 of Cftr. The HSV1 thymidine kinase (HSV1tk) gene was also introduced to allow back selection of targeted clones for introduction of specific mutations by the ‘hit and run’ procedure (14). The vector pHRNTF508 (Fig. 1B) was used to target the Cftr gene and 2 out of 53 (3.8%) clones obtained were identified as correctly targeted by Southern blot analysis. This frequency of homologous recombination represents a modest increase of 1.7-fold over that obtained using pIV3.5H (Table 1). Both vectors were linearised at the Asp718 site 0.4 kb from the 5' end of the target region of homology, but pHRNTF508 possesses an additional 0.8 kb of target sequence. Thus, an increase in the overall size of the genomic DNA used improved the frequency at which the region was targeted, in agreement with the data reported previously for targeting the Hprt gene (3,6,7). In order to determine whether the distribution of homology 5' and 3' of the site of linearisation affects the targeting efficiency at the Cftr locus, HpaI was used to linearise pHRNTF508 prior to targeting. This enzyme cuts in the genomic region 1.2 kb from the 5' and 3.1 kb from the 3' end of the target sequence. Linearising with HpaI more than doubled the frequency, with 9 out of 106 (8.5%) clones correctly targeted, as determined by Southern blot analysis (Fig. 2). Where others have reported dramatic variation in the targeting frequencies between experiments and cell lines (12,15), we found that this frequency of targeting could be reproduced using a different ES cell line. Using another 129 mouse strain derived cell line CGR8 (a generous gift of A. Smith), 7 out of 64 (10.9%) clones were correctly targeted (Table 1). The frequency of homologous recombination obtained with the HpaI cut pHRNTF508 vector (into either cell line)  represents an increase of ~4-fold over that obtained using pIV3.5H linearised with Asp718 (Table 1). Thus, altering the site of linearisation to give a more even distribution of homology gave a valuable increase in the efficiency of targeting over and above that obtained from simply increasing the amount of homology. The use of non-isogenic DNA constructs (6,8) and mutation containing marker genes (16) has been reported to reduce targeting frequencies. However, the presence of single base mismatches and a three base pair deletion introduced into pHRNTF508 did not appear to adversely affect the targeting efficiency of this vector. The site of the mutation is 3.2 kb and 2.4 kb from the Asp718 and HpaI sites respectively, thus we would not expect this to present an ‘end effect’ and interfere with the frequency of targeting (16). Experiments performed using pHRHTI507 (a similar vector containing a different mutation) gave a slightly lower targeting frequency in E14 cells (3 out of 74 (4.1%) clones correctly targeted) but similar high frequency in CGR8 cells (9 out of 86 (10.5%) clones correctly targeted).	 Our insertional vectors target at frequencies up to ~200-fold higher than those reported by Koller et al. (11) and Ratcliffe et al. (12). Snouwaert et al. (15), using the vector previously described by Koller et al (11), claim a Cftr targeting frequency of 1 in 300 (0.3%) in one isolated experiment. The authors suggest that unknown variables in this particular experiment were responsible for the increase in efficiency. This conclusion was reached because a parallel experiment with a control construct, targeting Hprt, also gave a 10-fold increase in targeting frequency over that routinely found. A much higher targeting frequency of 13 out of 96 (14%) positively and negatively selected clones has recently been reported by Deng et al. (17) using a replacement vector possessing 12 kb of target homology. It is not reported whether this result was repeatable in separate experiments, but the increased size of the target region in this replacement vector compared to that used in previous replacement experiments (5.5-7.8 kb) or these insertion experiments (3.5-4.3 kb) would be expected to have a positive effect on the intrinsic targeting frequency. Others also comment that targeting frequencies can vary dramatically between experiments, but in our hands targeting frequencies are very consistent. The ratio of targeted to non-targeted clones is highly reproducible both between the same experiment on various days and experiments using different cell lines. This latter point rules out the possibility that the E14 cell line used by us is responsible for our enhanced targeting frequencies. It is also unlikely that the E14TG2a cells used by both Koller et al. (11) and Ratcliffe et al. (12) has depressed their targeting frequencies, as Thompson et al. (18) report a 10-fold improvement in Hprt targeting frequency when using this cell line compared to those reported in similar experiments using a different cell line (3). The variation in targeting frequency between the replacement and insertional vectors cannot be explained in terms of DNA strain variation as all groups use partially overlapping subfragments derived from the same isogenic strain. In addition, Koller et al. (11) and Ratcliffe et al. (12) use replacement vectors derived from the same  genomic clone as ourselves, but with more homology to the Cftr gene than is present in our vectors. All other intrinsic factors being equal, we conclude that our Cftr insertional vectors give up to ~200-fold improved gene targeting frequencies over those reported for Cftr gene replacement vectors in mouse embryonal stem cells. Our frequencies with insertional vectors (and a single positive selection step) are at least equivalent to those reported for replacement vectors (17), even after the ~10-fold PNS (4) enrichment for targeted clones, and on average 2 orders of magnitude greater than typical replacement experiments (11,12). Our results thus contradict the claim of Deng and Capecchi (6) that there is no intrinsic difference in targeting frequencies of insertional and replacement vectors. Our data supports that of Hasty et al. (5) who report a nine-fold improved frequency of Hprt gene targeting with insertional versus replacement vectors. Our data however, does not support the finding of Hasty et al. (5), that the total length of homology in an insertional vector has a greater impact on targeting frequency than the length of homology surrounding the site of linearisation. They report no appreciable change in Hprt targeting frequency when cutting an insertional vector at two different sites within 1.3 kb of homology. It is probable in this specific circumstance, that the short length of total homology reduced the frequency of homologous recombination to such a degree that the effect of cutting the vector more centrally was masked. Our results indicate that while the overall amount of homology within an insertional vector is important, the primary factor affecting targeting frequency is the length of target homology on both sides of the linearisation site. The simplicity of construction and efficiency of gene targeting favour the use of insertional vectors for creating animal models for human genetic disease and determining gene function. They have the potential to create absolute or partial gene disruption and can introduce specific gene mutations via the ‘hit and run’ procedure (14). This elegant stategy results in the target locus being altered only by the predetermined sequence modifications. Specific mutations can also be introduced using a replacement vector where the positive selectable marker is contained within an intron, but this has the disadvantage that expression of the foreign DNA may subsequently interfere with expression of the targeted gene. The vectors described here have introduced both the F508 mutation (a severe CF mutation present on ~70% of all CF chromosomes (19)), and I507 (one of many, rarer mutations (20)). Both of these mutations produce CFTR protein that lacks one amino acid from the first nucleotide binding fold (19). The generation of mice with precise mutations provides the opportunity to define genotype/phenotype correlations and test pharmacological interventions specific to mutant proteins. The cell lines described here represent the first step aimed at establishing these Cftr mutations in the mouse.
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Figure 1. Cftr targeting vectors. The solid black line is Cftr homology in the vector, the thick black line offset represents exon 10. The thick dashed stripe is plasmid, the dark hatched and grey stripes represent the neo and thymidine kinase cassettes repectively, and the arrows represent the direction of transcription. Restriction sites are Asp718 (A), BamHI (B), EcoRI (E), HindIII (H), HpaI (Hp), SalI (Sa), SstII (Ss), XbaI (Xb), and XhoI (Xh). (A) Insertion vector pIV3.5H, (B) Insertion vector pHRNTF508. Construction of the insertion vector pIV3.5H has been described previously (10). ‘Hit and run’ vectors were constructed by PCR mutagenesis (21) and subcloning of fragments from pIV3.5H, from XT2 (the original genomic clone from which pIV3.5H was subcloned) and from pUC18HSV1tk (PvuII fragment cloned into HincII site, kind gift of R. E. Hill). A 1.5 kb XhoI/Asp718 fragment from pIV3.5H was cloned into the BamHI/Asp718 sites of pUC18HSV1tk. After removal of EcoRI sites in both promoters by partial digestion and filling with Klenow, a 1.8 kb Asp718/EcoRI fragment from XT2 was cloned into Asp718/EcoRI sites of the vector. PCR mediated mutagenesis was used to create mutations in exon 10 of Cftr. 25 base oligonucleotide primers were used to amplify exon 10 from positions 1530 - 1720 in the Cftr gene (22), complementary mutant primers were used in combination with these to generate mutant PCR products. These were digested with HindIII and cloned in place of the normal exon 10 in a 2 kb EcoRI fragment subcloned from XT2, and finally these mutant 2 kb EcoRI fragments were cloned into the EcoRI site of the vector. To create constructs possessing the hygromycin-thymidine kinase fusion gene vectors were digested with SstII/BamHI, a 7.4 kb fragment gel purified and ligated to a 3025 bp partial SstII/XhoI fragment from tgCMV/HyTK (Immunex Research and Development Corp.). The integrity and orientation of subcloning were confirmed throughout by double stranded sequencing.

Figure 2.  Insertional disruption of the Cftr gene using pHRNTF508. (A) Targeting scheme. The figure illustrates the normal (i) and predicted mutant (ii) structure around exon 10 of the Cftr gene after targeting with pHRNTF508. Restriction site abbreviations are the same as in Fig.1. The diagnostic restriction fragments and 0.6EH external probe are indicated. All vectors were electroporated into E14 (23) or CGR8 (a generous gift from A. Smith) embryonal stem cells as described previously (10). Activity of the neomycin cassette after removal of the EcoRI site in its promoter was assayed by transfection into E14 cells and found to be equivalent to that of pMC1neo(polyA) (Stratagene) (data not shown). Selection was carried out at 200 g/ml G418 for 12 days or 150 g/ml hygromycin for 8 days, after which colonies were picked, expanded and stored in liquid nitrogen. (B) Southern blot analysis of pHRNTF508 targeting experiment. DNA was isolated from pellets of ~5x106 cells, digested with appropriate restriction enzymes and analysed by Southern blot as described previously (10).  XbaI/SalI digests of G418r clones (obtained using pHRNTF508 linearised with HpaI) were hybridised with the 0.6EH genomic probe external to the vector indicated in (A). The upper hybridising fragment of ~6 kb represents the endogenous XbaI fragment that decreases to a novel ~5 kb XbaI/SalI fragment if disrupted by a correctly targeted event (-M). The signal in clone 10.12 is not visible due to reduced DNA loading. All correctly targeted clones show the correct 1:1 dosage of mutant to wild-type band. Restriction digestion of targeted clones followed by hybridisation with 0.6EH indicated precise integration and conservation of the site of linearisation (data not shown).



Table 1.  Targeting efficiency at the cftr locus with insertional vectors

                                                                                                                                                                                                                                
Vector	Cell line	Homology (kb)	Linearisation Site	Totalclones	No. targeted clones	Targeting Efficiency
		5'	3'		selected		( % )
                                                                                                                                                                                                                                
pIV3.5H	E14	0.4	3.1	Asp718	231	5	2.2
pHRNTF508	E14	0.4	3.9	Asp718	53	2	3.8
pHRNTF508A	E14	1.2	3.1	HpaI	106	9	8.5
pHRNTF508A	CGR8	1.2	3.1	HpaI	64	7	10.9

pHRHTI507pHRHTI507	E14CGR8	1.21.2	3.13.1	HpaIHpaI	7486	39	4.110.5
                                                                                                                                                                                                                                










